Jun 05, 2023 / 11:00PM GMT
Lavina Talukdar - Moderna, Inc. - Senior VP & Head of IR
Good evening, everyone, and welcome to Moderna's ASCO 2023 event. We're so happy to welcome you here. Today, we have both Stephen Hoge, President of the company; as well as Kyle Holen, Head of Therapeutics -- Oncology and Therapeutics, here to review some of the data that we presented at ASCO. As a reminder, this is an IR event, and we will be making forward-looking statements. Please refer to the Slide #2 on the webcast relating to the risks associated with everything we're about to say today. And with that, I will hand it over to Stephen.
Stephen Hoge - Moderna, Inc. - President
Great. Thank you, Lavina. So I'll make some brief remarks -- that's going to be a problem -- and then turn it over to Kyle to walk through the data. So first of all, thank you for everybody who's come here to hear this. We're really looking forward to completing the picture of our first primary analysis in this mRNA-4157, previously called PCV, now called individualized neoantigen therapy, Phase II trial. This trial, as you
Moderna Inc ASCO Call Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers